pirtobrutinib (Pending FDA Approval)

Brand and Other Names:
  • Print

Dosing & Uses

Mantle Cell Lymphoma

Pending FDA approval for mantle cell lymphoma (MCL) previously treated with Bruton’s kinase (BTK) inhibitor

Next:

Pharmacology

Mechanism of Action

Bruton tyrosine kinase (BTK) inhibitor forms a covalent bond with a cysteine residue in the BTK active site, leading to inhibition of BTK activity

BTK is a signaling molecule of the B-cell antigen receptor (BCR) and cytokine receptor pathways; in B cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.